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Objectives: Acromegaly is a rare, chronic, hormonal disorder caused by excessive 
growth hormone (GH) and insulin-like growth factor 1 (IGF-1) production resulting 
predominantly from pituitary adenoma. The objective was to test endocrinologist 
acceptability of the newly developed SAGIT tool in clinical practice. MethOds: 
SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level 
– IGF-1 – Tumour) is a Clinician-Reported Outcomes (ClinROs) tool developed with 
international experts in acromegaly; it allows patient classification and descrip-
tion in a standardised manner. The tool was pre-tested for acceptability, under-
standing and ease of use with practicing endocrinologists in France, Germany, UK, 
Spain, Italy and Brazil (n= 2 per country) using the PRAgmatic Content and face 
validity Test (PRAC-Test). The endocrinologists completed the SAGIT tool prior to 
and following an intervention (therapeutics or surgery) for three patients each 
(n= 36). Once completed, a one-hour phone interview was conducted with each 
endocrinologist to collect their feedback on the tool. Results: The tool was well 
accepted and deemed concise (n= 11) and informative (n= 10) by the endocrinolo-
gists. Several points were raised that illustrate its usefulness in clinical practice, 
including the removal of the subjectivity when assessing the disease severity, the 
possibility of rapid evaluation of the control/progression of acromegaly or of a 
treatment response, and the possibility for standardisation across countries. Key 
recommendations for improvements were the need to include: 1) instructions to 
facilitate the understanding and the use of the tool; 2) definitions of rules and 
recommendations for patient management; and 3) addition of other signs and 
symptoms and further details about tumour size to better reflect their clinical 
cases. cOnclusiOns: SAGIT is a useful tool for endocrinologists to accurately 
stage and classify acromegaly patients in clinical practice. It is currently being 
piloted in a cross-sectional study. Validation of scoring rules will confirm the utility 
of the tool to improve patient management.
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Objectives: Regular self-monitoring of using a blood glucose meter helps diabetic 
patients to adjust their management strategies proactively, thus avoiding diabetic 
complications which place a burden on health care resources. The aim of this study 
was to elicit diabetic patients’ preferences for different blood glucose meter attrib-
utes. MethOds: A cross-sectional, web-based survey of UK patients with Type 1 and 
type 2 diabetes was conducted in January 2013 and preferences for five key attributes 
associated with blood glucose meters were estimated using a discrete choice experi-
ment (DCE) framework. A foldover design and optimised orthogonal differences 
were considered, but the final choice experiment was a Bayesian d-efficient design. 
Responses were analysed using a conditional logit model in STATA 12.1. Results: 
Out of 447 responses, 406 (90.83%) patients were suitable for inclusion in the DCE 
analysis. Statistically significant differences (p< 0.05) were found between the Type 1 
and Type 2 sub-groups when comparing responder characteristics (years diagnosed, 
age, tests per day, number of comorbidities). Regarding glucose meter attributes, 
Type 1 respondents considered the ‘time to test’ to be the most critical factor and 
were willing to trade a compact device (2.61 units), or convenience (1.37 units) for 
a device that could produce test results in under 30 seconds. Type 2 respondents 
preferred the low maintenance attribute and were most willing to trade a compact 
device (2.72 units) or convenience (1.37 units) for this attribute. cOnclusiOns: This 
is the first DCE to examine the impact of blood glucose meter attributes on blood 
glucose meter choice and adherence. Devices that provide value added features such 
as offline storage of data and additional data analysis will be valued by both Type 1 
and Type 2 patients whereas a compact device is less valued.
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Objectives: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed 
for T2DM. GMM was used to evaluate the effects of canagliflozin versus sitaglip-
tin on WRQoL in subjects with T2DM. MethOds: Data were from 2 multinational, 
randomised, double-blind, Phase 3 trials: 1) subjects inadequately controlled with 
metformin (N= 1,284) receiving canagliflozin 100 or 300 mg, sitagliptin 100 mg, or 
placebo for 26 weeks with a 26-week extension (placebo switched to sitagliptin; 
dual therapy); and 2) subjects inadequately controlled with metformin plus a sul-
phonylurea (N= 755) receiving canagliflozin 300 mg or SITA 100 mg for 52 weeks 
(triple therapy). WRQoL was assessed using the Impact of Weight on Quality of 
Life-Lite (IWQOL-Lite) questionnaire. GMM was used to assess heterogeneity within 
samples to identify data-driven subgroups with differential changes in IWQOL-Lite 
total scores. Results: In both trials, GMM identified 2 subgroups per treatment 
arm: “subgroup 1” (81% and 87% of total trial samples) started with high scores 
(~85 points), while “subgroup 2” (19% and 13% of total trial samples) started with 
low scores (44-53 points). Subgroup 1 scores remained high throughout both tri-
als for all treatments. For the dual-therapy trial, subgroup 2 subjects treated with 
canagliflozin 100 or 300 mg had improvement (2.1 and 5.4 points, respectively), 
while those treated with sitagliptin 100 mg had declining scores (–4.0 points) over 
the course of the trial (P < 0.05). For the triple therapy trial, all subgroup 2 subjects 
improved; improvement was significantly greater with canagliflozin 300 mg versus 
sitagliptin 100 mg (19.6 vs 4.8 points; P< 0.05). In both trials, there were significant 
differences between the subgroups based upon baseline demographic, clinical, and 
patient-reported characteristics. cOnclusiOns: GMM applied to these trial data 
enabled identification of treatment effects that were masked by standard statisti-
cal techniques. Heterogeneity should be considered when analysing WRQoL data.
the translations. Ten to fifteen cognitive debriefing interviews were conducted 
in each country. Interviewees reported the measure to be easy to understand 
and complete and that the content was relevant without missing important 
issues. cOnclusiOns: The standards set by the existing UK version of the QoL-
AGHDA are high with internal consistency and test-retest reliability above 0.90. 
Construct validity was also demonstrated by the measure’s ability to distinguish 
between patients according to self-perceived general health and by correlating 
scores with those on the General Well Being Index (> 0.70). Completed validations 
have obtained a similar psychometric quality. Similar studies are underway to evalu-
ate the formal construct validity and reproducibility of these new language versions.
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Objectives: Assessment of patient’s perspectives of hypoglycemia burden may 
be of value to provide adequate management of type 2 diabetes (T2D) patients. 
The Hypoglycemia Perspectives Questionnaire (HPQ) is a new multidimensional 
instrument assessing patient’s experience of hypoglycemia. The goal of this study 
was to test the practicability and utility of HPQ-Russian version (HPQ-R) by means 
of its psychometric performance. MethOds: A total of 200 T2D patients receiving 
oral hypoglycemic therapy (59% – metformin; 41% – metformin plus vildagliptin or 
sulphonylureas, SU) were enrolled in the study: male/female 71/129; mean age – 
58.7 yrs; mean disease duration – 4.1 yrs. Mean HbA1c level was 7%. All the patients 
completed HPQ-R at baseline and after 2-3 months of treatment. Patients and physi-
cians were interviewed to test practicability of the instrument. Construct validity, 
reliability and sensitivity of the HPQ-R were assessed to provide its utility. Results: 
Both patients and physicians acknowledged the comprehensiveness of the tool for 
revealing hypoglycemia-related problems; physicians used information from it for 
their decision-making. It was easily understood by, and administered to patients: 
2.8% of missing values. An exploratory factor analysis revealed a strongly dimen-
sional instrument (explained 70% of total pooled variance), with Chronbach alphas 
≥ 0.9 for 6 out of 7 scales. Reproducibility of the tool was shown by comparing 
HPQ-R scores at two time-points for patients with effective HbA1c control receiving 
metformin plus vildagliptin: r= 0.53–0.87 for 5 scales (p< 0.05). HPQ-R scores were 
lower in patients with hypoglycemia events than in patients without hypoglycemia 
as well as in patients with severe hypoglycemia than in patients with non-severe 
hypoglycemia (p< 0.05). Increased occurrence of hypoglycemia events and worsening 
of scores for 4 HPQ scales was shown after switch from monotherapy to therapy 
metformin plus SU (p< 0.05). cOnclusiOns: Thus, the HPQ-R is a practical and use-
ful tool for comprehensive assessment of hypoglycemia experience in T2D patients.
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Objectives: Patients’ preferences and evaluation of treatment benefits/risks from 
patient’s perspective are increasingly being considered in decision-making regard-
ing treatment option. The goal of this prospective, open, observational study was to 
evaluate QoL and hypoglycemia burden in T2DM patients treated with vildagliptin 
and metformin as compared to those treated with sulphonylureas (SU) and met-
formin. MethOds: A total of 194 T2DM patients previously on oral monotherapy 
were enrolled in the study. 111 patients were selected by their treating physician to 
receive vildagliptin and metformin (cohort 1 – mean age 58 yrs; male/female 43/68) 
and 83 patients – SU and metformin (cohort 2– mean age 58.6 yrs; male/female 
27/56). Patient-reported outcomes were assessed at base-line and after approxi-
mately 3 mo using the SF-36 and the Hypoglycemia Perspectives Questionnaire 
(HPQ). For comparisons adjustment for age, sex, disease duration, complications 
and comorbidities was made. Results: QoL parameters for all SF-36 scales were 
significantly higher in cohort 1 as compared to cohort 2 after 3 mo of therapy 
(p< 0.01). Switch to vildagliptin plus metformin therapy was accompanied with 
remarkable increase of Integral QoL Index (p< 0.0001) whereas no changes of 
Integral QoL Index were observed after switch to SU plus metformin. After 3 mo 
of combination therapy the number of self-reported symptomatic hypoglycemic 
events was 16% in cohort 1 versus 70% in cohort 2; 12% of pts had severe hypogly-
cemic events in cohort 2. SU plus metformin therapy was accompanied with sig-
nificant hypoglycemia burden – after switching worries, awareness and symptom 
concern increased (p< 0.001). No changes were observed in cohort 1. The changes 
in glycemic control were the same in both cohorts: DHbA1c= 0.8%. cOnclusiOns: 
Benefits of vildagliptin plus metformin combination therapy in terms of improved 
QoL and reduced hypoglycemia burden in T2DM patients were shown. This therapy 
is an effective and preferable treatment in daily medical practice from patient’s 
perspective.
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